Skip to main content

Table 1 Baseline characteristics of patients aged ≥ 65 years (n = 108)

From: The effect of pegylated interferon-alpha2b and ribavirin combination therapy for chronic hepatitis C infection in elderly patients

Category

n or mean ± SD

Gender (Male/Female)

54/54

Age

68.2 ± 2.8

Body Weight (kg)

58.4 ± 9.5

Body mass index (kg/m2)

23.3 ± 3.0

History of interferon therapy (yes/no)

40/68

History of diabetes mellitus (yes/no)

19/89

History of hypertension (yes/no)

47/61

White blood cells (/mm3)

4909 ± 1332

Red blood cells (× 104/mm3)

436.1 ± 39.8

Hemoglobin (g/dL)

13.8 ± 1.2

Platelets (× 104/mm3)

15.3 ± 3.9

AST (IU/L)

65.2 ± 37.3

ALT (IU/L)

76.0 ± 65.5

AFP (ng/ml)

15.7 ± 31.4

Histology (METAVIR) Fibrosis (1/2/3/4)

22/41/37/8

Histology (METAVIR) Activity (1/2/3)

30/51/27

HCV genotype (1/2)

86/22

Serum HCV RNA (KIU/ml)

1650 ± 1521

Peg-IFN dose (g/kg/week)

1.22 ± 0.32

Total Peg-IFN dose > 80% (yes/no)

63/45

Daily ribavirin dose (mg/kg)

9.58 ± 2.93

Total ribavirin dose > 80% (yes/no)

63/45

  1. Data are shown as absolute values or mean ± standard deviation. AST aspartate aminotransferase; ALT alanine aminotransferase; AFP alpha-fetoprotein; HCV hepatitis C virus; Peg-IFN pegylated interferon